BUSULFAN injection, solution, concentrate

Country: Amerika Syarikat

Bahasa: Inggeris

Sumber: NLM (National Library of Medicine)

Bahan aktif:

Busulfan (UNII: G1LN9045DK) (Busulfan - UNII:G1LN9045DK)

Boleh didapati daripada:

Sagent Pharmaceuticals

INN (Nama Antarabangsa):

Busulfan

Komposisi:

Busulfan 6 mg in 1 mL

Laluan pentadbiran:

INTRAVENOUS

Jenis preskripsi:

PRESCRIPTION DRUG

Tanda-tanda terapeutik:

Busulfan Injection is indicated for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia. Busulfan Injection is contraindicated in patients with a history of hypersensitivity to any of its components. Risk Summary Busulfan can cause fetal harm when administered to a pregnant woman based on animal data. Busulfan was teratogenic in mice, rats, and rabbits following administration during organogenesis. The solvent, DMA, may also cause fetal harm when administered to a pregnant woman. In rats, DMA doses of approximately 40% of the daily dose of DMA in the Busulfan Injection dose on a mg/m2 basis given during organogenesis caused significant developmental anomalies (see Data) . There are no available human data informing the drug-associated risk. Advise pregnant women of the potential risk to a fetus. The background risk of major birth defects and miscarriage for the indicated populations are unknown.

Ringkasan produk:

Busulfan Injection is supplied as follows: For Intravenous Infusion Only Busulfan Injection diluted in 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP is stable at room temperature (25°C) for up to 8 hours but the infusion must be completed within that time. Busulfan Injection diluted in 0.9% Sodium Chloride Injection, USP is stable at refrigerated conditions (2°C to 8°C) for up to 12 hours but the infusion must be completed within that time. Busulfan Injection is a cytotoxic drug. Follow applicable special handling and disposal procedures.1 Storage Conditions Store refrigerated between 2° and 8°C (36° and 46°F). Discard unused portion. Sterile, Nonpyrogenic, Preservative-free. The container closure is not made with natural rubber latex.

Status kebenaran:

Abbreviated New Drug Application

Ciri produk

BUSULFAN- BUSULFAN INJECTION, SOLUTION, CONCENTRATE
SAGENT PHARMACEUTICALS
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
BUSULFAN INJECTION SAFELY AND
EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR BUSULFAN INJECTION.
BUSULFAN INJECTION, FOR INTRAVENOUS INFUSION
INITIAL U.S. APPROVAL: 1999
WARNING: MYELOSUPPRESSION
_SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._
CAUSES SEVERE AND PROLONGED MYELOSUPPRESSION. (5.1)
HEMATOPOIETIC PROGENITOR CELL TRANSPLANTATION IS REQUIRED TO PREVENT
POTENTIALLY FATAL COMPLICATIONS
OF THE PROLONGED MYELOSUPPRESSION. (5.1)
INDICATIONS AND USAGE
Busulfan Injection is an alkylating drug indicated for:
Use in combination with cyclophosphamide as a conditioning regimen
prior to allogeneic hematopoietic progenitor cell
transplantation for chronic myelogenous leukemia (CML) (1)
DOSAGE AND ADMINISTRATION
Pre-medicate with anticonvulsants (e.g. benzodiazepines, phenytoin,
valproic acid or levetiracetam) and antiemetic (2.1,
5.2)
Dilute and administer as intravenous infusion. Do not administer as
intravenous push or bolus (2.1, 2.3)
Recommended adult dose: 0.8 mg per kg of ideal body weight or actual
body weight, whichever is lower, administered
intravenously via a central venous catheter as a two-hour infusion
every six hours for four consecutive days for a total
of 16 doses (2.1)
DOSAGE FORMS AND STRENGTHS
Injection: 60 mg per 10 mL (6 mg per mL) single-dose vial (3)
CONTRAINDICATIONS
Busulfan Injection is contraindicated in patients with a history of
hypersensitivity to any of its components (4)
WARNINGS AND PRECAUTIONS
Seizures: Initiate anticonvulsant prophylactic therapy prior to
treatment with Busulfan Injection. Monitor patients with
history of seizure disorder, head trauma or receiving epileptogenic
drugs (5.2)
Hepatic Veno-Occlusive Disease (HVOD): Increased risk of developing
HVOD at AUC greater than 1,500 μM•min.
Monitor serum transaminases, alkaline phosphatase and bilirubin daily
(5.3)
Embr